FAMILY SITE

Specialized in the development of cord blood-derived immune cell therapeutics

Immunique

IMMUNIQUE develops cord blood-derived immune cell therapeutics to treat intractable diseases
including autoimmune diseases and immunodeficiency-related diseases.

R&D

Global solution to save lives

IMMUNIQUE’s technology presents new possibilities

Treg
Cell Therapeutics

IMMUNIQUE develops cutting-edge cell therapeutics that maximize the characteristics of Treg cells derived from cord blood, maintaining immune balance and normalizing the immune system

R&D

Global solution to save lives

IMMUNIQUE’s technology presents new possibilities

IMMUNIQUE’s
Pipeline

R&D

Global solution to save lives

IMMUNIQUE’s technology presents new possibilities

IMQ101-GvHD

Graft-versus-host disease (GvHD) occurs when T cells from a donor mistakenly attack the recipient’s normal cells after allogeneic hematopoietic stem cell transplantation (HSCT)

R&D

Global solution to save lives

IMMUNIQUE’s technology presents new possibilities

IMQ101-AA

Aplastic anemia (AA), a rare autoimmune disorder, occurs from insufficient production of red blood cells, white blood cells, and platelets due to bone marrow failure caused by cytotoxic T cells.

R&D

Global solution to save lives

IMMUNIQUE’s technology presents new possibilities

IMQ301/302

Autoimmune Disease is a condition where the immune system mistakenly attacks its own tissues and cells. Autoimmune diseases are chronic and require appropriate medical treatment

Immunique

News

Check out various news from Immunique.

Connect
with
Immunique